capecitabine + irinotecan + fluorouracil + leucovorin

Capecitabine + irinotecan + 5-fluorouracil + calciumfolinat is a multi-agent chemotherapy combination regimen used in the treatment of metastatic colorectal cancer (mCRC). It combines capecitabine (an oral fluoropyrimidine prodrug that is metabolized to 5-fluorouracil in tumor tissues), irinotecan (a topoisomerase I inhibitor), 5-fluorouracil (a pyrimidine analog antimetabolite), and leucovorin (calcium folinate, a folate derivative that potentiates 5-fluorouracil activity). This combination was investigated in a randomized phase III trial (NCT00149799) sponsored by Vejle Hospital in Denmark. The study aimed to compare standard single-agent chemotherapy against a tailored treatment approach based on genetic markers, specifically thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR), in older patients with advanced colorectal cancer. The regimen targets key enzymes in DNA replication and repair, primarily thymidylate synthase and topoisomerase I. It is not a commercially available fixed-dose combination but rather a research-based protocol using individual approved agents.

Other names

capecitabine + irinotecan + 5-fluorouracil + calciumfolinatcapecitabine + irinotecan + 5-FU + LVcapecitabine + irinotecan + 5-FU + leucovorin